Analysts expect Phio Pharmaceuticals Corp. to report revenue of 0.00 for Q3 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 0.00.
| Metric | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | - | - | - | - | - | - | - | - | ||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Phio Pharmaceuticals Corp. to report earnings per share of -0.34 for Q3 26, against a range of -0.36 to -0.32. The most recent reported quarter, Q2 26, came in at -0.36, a 5.3% beat against the -0.38 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -1.54 | 0.31 | -0.41 | -0.45 | -0.44 | -0.15 | -0.34 | -0.36 | - | - | - | - | - | - | - | - | ||
| High Estimate | -3.91 | -1.08 | - | -0.32 | -0.40 | -0.31 | -0.22 | -0.36 | -0.32 | -0.35 | -0.12 | -0.09 | -0.04 | 0.04 | -0.06 | 0.03 | ||
| Low Estimate | -4.65 | -1.30 | - | -0.36 | -0.48 | -0.33 | -0.26 | -0.40 | -0.36 | -0.39 | -0.14 | -0.09 | -0.04 | 0.04 | -0.08 | 0.03 | ||
| Consensus Estimate | -4.28 | -1.19 | - | -0.34 | -0.44 | -0.32 | -0.24 | -0.38 | -0.34 | -0.37 | -0.13 | -0.09 | -0.04 | 0.04 | -0.07 | 0.03 |